Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS | ($2.1) | ($2.3) | ($1.8) | ($3.0) | ($3.3) | ($3.7) | ($3.8) | $0.1 | ($0.5) | ($2.0) | ($3.1) | ($2.3) | ($0.5) | $1.1 | $8.3 | $4.6 | $10.4 | $9.1 | $13.0 | $14.1 |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Vertex Pharmaceuticals Incorporated's last 12-month EPS is ($1.9), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Vertex Pharmaceuticals Incorporated's EPS growth was N/A. The average annual EPS growth rates for Vertex Pharmaceuticals Incorporated have been N/A over the past three years, N/A over the past five years.